Bluefish wins tender auction in Spain

Two-year contract for Bluefish products in Andalusia region

Bluefish has been selected as the semi-exclusive provider for Escitalopram 10mg and Losartan HCTZ 100/25mg and exclusive provider for Escitalopram 5mg/20mg, Levetiracetam 1mg, Levofloxacin 500mg, Mirtazapine ODT 15/30/45mg and Quetiapine SR 50/200/300/400mg in a two-year supply contract with the SAS (Servicio Andaluz de Salud). With a total of 15 references awarded, Bluefish ranked as second in the Andalusia tender for offers submitted in June 2014. Initial supply is planned for end of 2014. The net sales value from the contract is estimated to approximately SEK 70 million over a two-year period.

Bluefish has previously been selected as the exclusive provider of certain oncology products to SAS. While tender auctions for pharmaceuticals are common practice throughout Europe, so far, Andalusia is the only one of Spain‘s 17 different regions where this method is applied.

Bluefish has successfully built market share in major European markets by offering high quality generic pharmaceuticals. Never compromising on product quality and patient safety, Bluefish markets products in an innovative, responsible and cost-efficient way with the ambition of making modern medicines accessible to more people.

Bluefish is operating in a large number of European markets. The product portfolio consists of 80 products and is growing.

For more information, contact

Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: karl.karlsson@bluefishpharma.com

Susanna Urdmark, CFO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: susanna.urdmark@bluefishpharma.com

About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of 80 products and is growing.

www.bluefishpharma.com

About Us

Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of 80 products and is growing. The company is owned by its founder Karl Karlsson, together with a number of investment funds and private investors.